AN ISO 9001 : 2015 CERTIFIED COMPANY

Detailed project report
Sample edition
Projections from FY 2027-28

Project report

# Moringa Tablets

Installed capacity 4,00,000 tablets per day
Sector Pharmaceuticals
Total project cost ₹499.97 lakh

**Illustrative sample**
Figures are representative

**Niir Project Consultancy Services**
106-E, Kamla Nagar, New Delhi 110007, India

www.niir.org
+91 90970 75054 | npcs.india@gmail.com

# Project at a glance

Moringa Tablets
4,00,000 tablets per day

| | | | |
|---|---|---|---|
| Product | **Moringa Tablets** | Sector | **Pharmaceuticals** |
| Installed capacity | **4,00,000 tablets per day** | Annual capacity | **12,00,00,000 tablets per year** |
| Selling price (ex-GST) | **₹1.24 per tablet** | Working days | **300 a year** |
| Manpower | **39 people** | Plant and machinery | **₹202.85 lakh** |
| Total project cost | **₹499.97 lakh** | Promoter's contribution | **₹124.99 lakh (25%)** |
| Term loan | **₹374.98 lakh (75%)** | Cash credit limit | **₹153.76 lakh** |
| Revenue, Year 3 | **₹1,041.60 lakh at 70%** | Net profit, Year 3 | **₹150.08 lakh** |
| Return on investment | **30.0% a year** | Break-even, Year 3 | **39.0% of capacity** |
| Average DSCR | **2.21** | Payback period | **3.0 years** |

This is an illustrative sample. Its figures are generated from industry-typical ratios to show the format and depth of an NPCS project report. They are not taken from any NPCS report or any real project, and should not be used for investment or lending decisions.

## Contents

1 Introduction
2 Uses and applications
3 Market potential
4 Manufacturing process
5 Raw materials
6 Plant and machinery
7 Land, building and utilities
8 Manpower
9 Licences and approvals
10 Project cost and means of finance
11 Working capital
12 Projected profitability
13 Cash flow statement
14 Projected balance sheet
15 Depreciation
16 Term loan repayment
17 Debt service coverage
18 Break-even analysis
19 Financial ratios
20 Key assumptions
21 Conclusion
A Annexure: monthly loan repayment schedule

Illustrative sample

# 1 Introduction

The product covered in this sample is moringa tablets, made in a plant sized at 4,00,000 tablets per day (12,00,00,000 tablets per year at full capacity). The unit is costed as a complete project, from land and building through to working capital, and its applications range from daily nutrition and wellness supplements to bulk tablet exports to supplement packers.

Each section follows the layout of a bank-format project report: project cost, means of finance, working capital, profitability, cash flow, balance sheet, debt service and break-even. In Year 3, running at 70% of capacity, the model unit sells ₹1,041.60 lakh worth of moringa tablets and keeps ₹150.08 lakh as net profit.

# 2 Uses and applications

Demand for the product comes mainly from the following uses:

- Daily nutrition and wellness supplements
- Third-party manufacturing for nutraceutical and Ayurvedic brands
- Online and pharmacy supplement retail
- Bulk tablet exports to supplement packers

# 3 Market potential

Most moringa tablets in India are sold by wellness, Ayurvedic and online supplement brands that do not own a tablet plant, so third-party manufacturing for these brands is the steadiest business for a new unit. A smaller share is sold under the unit's own brand through pharmacies, health stores and marketplaces. Units compete on consistent powder quality, tested microbial limits and the right licence for the way the brand sells the product.


Typical buyers include nutraceutical and wellness brands, ayurvedic and herbal brands buying on loan licence or contract, online supplement sellers, pharmacies and health stores, and exporters and overseas supplement packers.

For a real project, the market survey is redone for the chosen location, covering present demand, expected growth and the existing manufacturers nearby.

Illustrative sample

# 4 Manufacturing process

The plant converts raw materials into finished moringa tablets in eight steps, shown in the flow chart and described below.




Process flow for moringa tablets

1. **Sifting and testing powder.** Bought-in moringa leaf powder is tested for moisture and microbial load and sifted to a uniform 60 to 80 mesh.
2. **Dispensing.** Leaf powder, binders and fillers are weighed for each batch in a dust-controlled dispensing room.
3. **Wet granulation.** The powders are mixed with binder solution in a rapid mixer granulator because leaf powder alone does not flow or compress well.
4. **Drying and sizing.** Wet granules are dried in a fluid bed dryer to low moisture and passed through a multi mill for even size.
5. **Blending.** Dried granules are blended with lubricants and glidants so they fill the dies evenly.
6. **Compression.** A rotary press compresses the granules into tablets of set weight, usually 500 mg, with checks on weight, hardness and friability.
7. **Coating.** Tablets are film coated to mask the grassy taste and protect the leaf powder from moisture.
8. **Packing.** Tablets are counted into HDPE bottles with induction-sealed caps or packed in blisters, then labelled with batch details.

Illustrative sample

# 5 Raw materials

The main raw materials are moringa oleifera leaf powder, binders and fillers such as microcrystalline cellulose and maize starch, film coating material, and lubricants and glidants. In Year 3, at 70% utilisation, raw materials cost ₹391.49 lakh, about 37.6% of sales. The table shows how this cost splits between materials.

| Raw material | Share of cost | Year 3 cost (₹ lakh) |
|---|---|---|
| Moringa oleifera leaf powder | 80.0% | 313.19 |
| Binders and fillers such as microcrystalline cellulose and maize starch | 11.0% | 43.06 |
| Film coating material | 6.0% | 23.49 |
| Lubricants and glidants | 3.0% | 11.75 |
| **Total raw materials** | **100.0%** | **391.49** |

# 6 Plant and machinery

Plant and machinery accounts for ₹202.85 lakh of the project cost. The rotary tablet compression machine takes the largest share, and the other items and their indicative costs are listed below.

| Machinery and equipment | Indicative cost (₹ lakh) |
|---|---|
| Vibro sifter and multi mill | 16.23 |
| Rapid mixer granulator | 28.40 |
| Fluid bed dryer | 26.37 |
| Octagonal or double cone blender | 12.17 |
| Rotary tablet compression machine | 48.68 |
| Auto coater | 20.29 |
| Bottle counting, filling and induction sealing line | 24.34 |
| Purified water system and dust extraction | 14.20 |
| Quality control laboratory instruments | 12.17 |
| **Total plant and machinery** | **202.85** |

# 7 Land, building and utilities

Land and site development is taken at ₹27.79 lakh and building and civil works at ₹153.70 lakh. Other fixed assets, including electrification, furniture, testing equipment and power backup, add ₹35.60 lakh. Land rates vary widely by location, so these are the figures most likely to change in a real project.

Utilities in Year 3 cost ₹28.63 lakh for power and fuel, or 2.7% of sales. The plant also needs a reliable water supply for cleaning and domestic use, and for the process where required.

Illustrative sampl

# 8 Manpower

A team of 39 runs the plant, from management and supervision to skilled operators and helpers. The Year 1 wage bill is ₹98.76 lakh, rising 5% a year.

| Category | Number | Monthly wage (₹) | Annual cost (₹ lakh) |
|---|---|---|---|
| Management, supervision and administration | 6 | 36,000 | 25.92 |
| Skilled workers and operators | 14 | 23,000 | 38.64 |
| Semi-skilled and unskilled workers | 19 | 15,000 | 34.20 |
| **Total (Year 1)** | **39** | | **98.76** |

# 9 Licences and approvals

The main registrations and approvals for a unit like this are listed below. They differ from state to state, so check the current requirements with the relevant departments.

- Udyam (MSME) registration
- GST registration
- Consent to establish and consent to operate from the State Pollution Control Board
- Factory licence or registration under the applicable labour law, where the workforce threshold applies
- Fire safety NOC, where required
- Trade licence from the local body
- FSSAI licence under the Health Supplements and Nutraceuticals Regulations 2022 when sold as a health supplement
- Ayurvedic drug manufacturing licence under rule 153 of the Drugs and Cosmetics Rules when sold as an Ayurvedic medicine
- GMP certificate for Ayurvedic drugs as per Schedule T for the Ayurvedic route
- Tablet quality tests as per the Indian Pharmacopoeia or Ayurvedic Pharmacopoeia of India

Illustrative sample

# 10 Project cost and means of finance

Project cost is estimated at ₹499.97 lakh, including fixed assets of ₹437.77 lakh and margin money for working capital of ₹51.26 lakh.

| Cost of project | ₹ lakh |
|---|---|
| Land and site development | 27.79 |
| Building and civil works | 153.70 |
| Plant and machinery | 202.85 |
| Other fixed assets (electrification, furniture, lab equipment, DG set) | 35.60 |
| Contingencies | 17.83 |
| Preliminary and pre-operative expenses | 10.94 |
| Margin money for working capital | 51.26 |
| **Total cost of project** | **499.97** |

## Means of finance

Funding follows a 75:25 split between bank loan and promoter's contribution, with a term loan of ₹374.98 lakh and promoter funds of ₹124.99 lakh. The bank also provides a cash credit limit of ₹153.76 lakh for working capital.

| Source of funds | ₹ lakh |
|---|---|
| Promoter's contribution (25%) | 124.99 |
| Term loan from bank (75%) | 374.98 |
| **Total means of finance** | **499.97** |
| *Cash credit limit for working capital (separate)* | *153.76* |

Illustrative sample

# 11 Working capital

Working capital is worked out from holding periods: 45 days of raw material, 30 days of finished goods and 60 days of credit to customers, less 30 days of credit from suppliers. In Year 1 the requirement is ₹205.02 lakh. The bank funds ₹153.76 lakh through cash credit and the promoter's margin covers ₹51.26 lakh.

| Particulars (₹ lakh) | Year 1 FY 2027-28 | Year 2 FY 2028-29 | Year 3 FY 2029-30 | Year 4 FY 2030-31 | Year 5 FY 2031-32 |
|---|---|---|---|---|---|
| Raw material stock (45 days) | 41.37 | 44.82 | 48.27 | 51.71 | 55.16 |
| Work in progress (5 days) | 6.29 | 6.76 | 7.25 | 7.73 | 8.22 |
| Finished goods (30 days) | 45.08 | 48.54 | 52.03 | 55.54 | 59.07 |
| Trade receivables (60 days) | 146.76 | 158.99 | 171.22 | 183.45 | 195.68 |
| **Total current assets** | **239.50** | **259.11** | **278.77** | **298.43** | **318.13** |
| Less: trade creditors (30 days) | 34.48 | 37.35 | 40.22 | 43.10 | 45.97 |
| **Working capital requirement** | **205.02** | **221.76** | **238.55** | **255.33** | **272.16** |


Illustrative sampl

# 12 Projected profitability

The unit is profitable from the first year, with a net profit of ₹93.26 lakh on sales of ₹892.80 lakh. By Year 5 sales reach ₹1,190.40 lakh and net profit ₹206.72 lakh, giving an average net margin of 14.2% across the projection.


| Particulars (₹ lakh) | Year 1 FY 2027-28 | Year 2 FY 2028-29 | Year 3 FY 2029-30 | Year 4 FY 2030-31 | Year 5 FY 2031-32 |
|---|---|---|---|---|---|
| *Capacity utilisation (%)* | *60%* | *65%* | *70%* | *75%* | *80%* |
| **Revenue from operations** | **892.80** | **967.20** | **1,041.60** | **1,116.00** | **1,190.40** |
| Raw materials consumed | 335.56 | 363.52 | 391.49 | 419.45 | 447.41 |
| Packing materials | 83.91 | 90.91 | 97.90 | 104.89 | 111.89 |
| Power and fuel | 24.54 | 26.59 | 28.63 | 30.68 | 32.72 |
| Wages and salaries | 98.76 | 103.70 | 108.88 | 114.33 | 120.04 |
| Repairs and maintenance | 4.06 | 4.26 | 4.47 | 4.70 | 4.93 |
| Insurance | 1.64 | 1.64 | 1.64 | 1.64 | 1.64 |
| **Cost of production** | **548.47** | **590.62** | **633.01** | **675.69** | **718.63** |
| **Gross profit** | **344.33** | **376.58** | **408.59** | **440.31** | **471.77** |
| Selling and distribution expenses | 61.97 | 67.13 | 72.30 | 77.46 | 82.63 |
| Administrative overheads | 48.61 | 51.04 | 53.60 | 56.28 | 59.09 |
| **Operating profit (EBITDA)** | **233.75** | **258.41** | **282.69** | **306.57** | **330.05** |
| Depreciation | 51.65 | 44.88 | 39.03 | 33.99 | 29.61 |
| Preliminary expenses written off | 2.19 | 2.19 | 2.19 | 2.19 | 2.18 |
| Interest on term loan | 38.65 | 32.43 | 24.45 | 15.58 | 5.73 |
| Interest on cash credit | 16.91 | 16.91 | 16.91 | 16.91 | 16.91 |
| **Profit before tax** | **124.35** | **162.00** | **200.11** | **237.90** | **275.62** |
| Income tax | 31.09 | 40.50 | 50.03 | 59.48 | 68.90 |
| **Profit after tax** | **93.26** | **121.50** | **150.08** | **178.42** | **206.72** |

Illustrative sample




Revenue, total cost before tax and net profit after tax, ₹ lakh

## Where each rupee of sales goes in Year 3




Each cost head as a percentage of Year 3 sales

Illustrative sample

# 13 Cash flow statement

The cash flow statement sets out the sources and uses of funds year by year. The unit stays cash positive throughout and closes Year 5 with a cash balance of ₹517.96 lakh after meeting the loan repayments due.

| Particulars (₹ lakh) | Year 1 FY 2027-28 | Year 2 FY 2028-29 | Year 3 FY 2029-30 | Year 4 FY 2030-31 | Year 5 FY 2031-32 |
|---|---|---|---|---|---|
| **Sources of funds** | | | | | |
| Promoter's contribution | 124.99 | – | – | – | – |
| Term loan from bank | 374.98 | – | – | – | – |
| Cash credit (working capital) from bank | 153.76 | – | – | – | – |
| Net profit after tax | 93.26 | 121.50 | 150.08 | 178.42 | 206.72 |
| Depreciation | 51.65 | 44.88 | 39.03 | 33.99 | 29.61 |
| Preliminary expenses written off | 2.19 | 2.19 | 2.19 | 2.19 | 2.18 |
| Increase in trade creditors | 34.48 | 2.87 | 2.87 | 2.88 | 2.87 |
| **Total sources** | **835.31** | **171.44** | **194.17** | **217.48** | **241.38** |
| **Application of funds** | | | | | |
| Fixed assets | 437.77 | – | – | – | – |
| Preliminary and pre-operative expenses | 10.94 | – | – | – | – |
| Increase in inventories | 92.74 | 7.38 | 7.43 | 7.43 | 7.47 |
| Increase in trade receivables | 146.76 | 12.23 | 12.23 | 12.23 | 12.23 |
| Repayment of term loan | 33.50 | 72.48 | 80.47 | 89.34 | 99.19 |
| Drawings | – | – | – | – | – |
| **Total application** | 721.71 | 92.09 | 100.13 | 109.00 | 118.89 |
| **Net cash flow** | **113.60** | **79.35** | **94.04** | **108.48** | **122.49** |
| Opening cash balance | – | 113.60 | 192.95 | 286.99 | 395.47 |
| **Closing cash balance** | **113.60** | **192.95** | **286.99** | **395.47** | **517.96** |

Illustrative sample

# 14 Projected balance sheet

The projected balance sheet balances in every year. Net worth grows from ₹209.50 lakh at the end of Year 1 to ₹874.97 lakh at the end of Year 5, while the term loan outstanding falls from ₹341.48 lakh to nil.

| As at year end (₹ lakh) | Year 1 FY 2027-28 | Year 2 FY 2028-29 | Year 3 FY 2029-30 | Year 4 FY 2030-31 | Year 5 FY 2031-32 |
|---|---|---|---|---|---|
| **Liabilities** | | | | | |
| Promoter's capital | 124.99 | 124.99 | 124.99 | 124.99 | 124.99 |
| Reserves and surplus | 93.26 | 214.76 | 364.84 | 543.26 | 749.98 |
| Term loan | 341.48 | 269.00 | 188.53 | 99.19 | – |
| Cash credit from bank | 153.76 | 153.76 | 153.76 | 153.76 | 153.76 |
| Trade creditors | 34.48 | 37.35 | 40.22 | 43.10 | 45.97 |
| **Total liabilities** | **747.97** | **799.86** | **872.34** | **964.30** | **1,074.70** |
| **Assets** | | | | | |
| Gross fixed assets | 437.77 | 437.77 | 437.77 | 437.77 | 437.77 |
| Less: accumulated depreciation | (51.65) | (96.53) | (135.56) | (169.55) | (199.16) |
| **Net fixed assets** | **386.12** | **341.24** | **302.21** | **268.22** | **238.61** |
| Preliminary expenses not written off | 8.75 | 6.56 | 4.37 | 2.18 | – |
| Inventories | 92.74 | 100.12 | 107.55 | 114.98 | 122.45 |
| Trade receivables | 146.76 | 158.99 | 171.22 | 183.45 | 195.68 |
| Cash and bank balance | 113.60 | 192.95 | 286.99 | 395.47 | 517.96 |
| **Total assets** | **747.97** | **799.86** | **872.34** | **964.30** | **1,074.70** |

Illustrative sample

# 15 Depreciation

Depreciation is charged on the written-down value method at Income Tax Act rates: 10% on building, 15% on plant and machinery and 10% on other fixed assets. Land is not depreciated, and preliminary expenses are written off over five years.

| Particulars (₹ lakh) | Year 1 FY 2027-28 | Year 2 FY 2028-29 | Year 3 FY 2029-30 | Year 4 FY 2030-31 | Year 5 FY 2031-32 |
|---|---|---|---|---|---|
| Building and civil works (cost ₹161.39 lakh, 10% WDV) | | | | | |
| Opening written-down value | 161.39 | 145.25 | 130.73 | 117.66 | 105.89 |
| Depreciation | 16.14 | 14.52 | 13.07 | 11.77 | 10.59 |
| **Closing written-down value** | **145.25** | **130.73** | **117.66** | **105.89** | **95.30** |
| Plant and machinery (cost ₹212.99 lakh, 15% WDV) | | | | | |
| Opening written-down value | 212.99 | 181.04 | 153.88 | 130.80 | 111.18 |
| Depreciation | 31.95 | 27.16 | 23.08 | 19.62 | 16.68 |
| **Closing written-down value** | **181.04** | **153.88** | **130.80** | **111.18** | **94.50** |
| Other fixed assets (cost ₹35.60 lakh, 10% WDV) | | | | | |
| Opening written-down value | 35.60 | 32.04 | 28.84 | 25.96 | 23.36 |
| Depreciation | 3.56 | 3.20 | 2.88 | 2.60 | 2.34 |
| **Closing written-down value** | **32.04** | **28.84** | **25.96** | **23.36** | **21.02** |
| **Total depreciation** | **51.65** | **44.88** | **39.03** | **33.99** | **29.61** |
| Preliminary expenses written off | 2.19 | 2.19 | 2.19 | 2.19 | 2.18 |

# 16 Term loan repayment

Repayment of the ₹374.98 lakh term loan starts after a moratorium of 6 months, during which interest at 10.5% is serviced. The loan is then cleared in 54 EMIs of ₹8,74,311 each, and the annexure gives the monthly schedule.


| Particulars (₹ lakh) | Year 1 FY 2027-28 | Year 2 FY 2028-29 | Year 3 FY 2029-30 | Year 4 FY 2030-31 | Year 5 FY 2031-32 |
|---|---|---|---|---|---|
| Opening balance | 374.98 | 341.48 | 269.00 | 188.53 | 99.19 |
| Interest | 38.65 | 32.43 | 24.45 | 15.58 | 5.73 |
| Principal repaid | 33.50 | 72.48 | 80.47 | 89.34 | 99.19 |
| **Closing balance** | **341.48** | **269.00** | **188.53** | **99.19** | **–** |

Illustrative sample

# 17 Debt service coverage

Cash available for debt service covers the term loan instalments 2.21 times on average, and never less than 1.92 times (Year 2).

| Particulars (₹ lakh) | Year 1 FY 2027-28 | Year 2 FY 2028-29 | Year 3 FY 2029-30 | Year 4 FY 2030-31 | Year 5 FY 2031-32 |
|---|---|---|---|---|---|
| Net profit after tax | 93.26 | 121.50 | 150.08 | 178.42 | 206.72 |
| Depreciation and write-offs | 53.84 | 47.07 | 41.22 | 36.18 | 31.79 |
| Interest on term loan | 38.65 | 32.43 | 24.45 | 15.58 | 5.73 |
| **Total available for debt service (A)** | **185.75** | **201.00** | **215.75** | **230.18** | **244.24** |
| Principal repayment | 33.50 | 72.48 | 80.47 | 89.34 | 99.19 |
| Interest on term loan | 38.65 | 32.43 | 24.45 | 15.58 | 5.73 |
| **Total debt service (B)** | **72.15** | **104.91** | **104.92** | **104.92** | **104.92** |
| DSCR (A / B) | 2.57 | 1.92 | 2.06 | 2.19 | 2.33 |





DSCR by year. A ratio above 1.00 means cash accruals cover the term loan instalments.

Illustrative sample

# 18 Break-even analysis

The break-even point in Year 3 is 39% of installed capacity. Below that level the unit would not cover its fixed costs, interest and depreciation; above it, each additional unit sold adds to profit. Cash break-even is lower, at 32.6%.

| Particulars (₹ lakh) | Year 1 FY 2027-28 | Year 2 FY 2028-29 | Year 3 FY 2029-30 | Year 4 FY 2030-31 | Year 5 FY 2031-32 |
|---|---|---|---|---|---|
| Revenue from operations | 892.80 | 967.20 | 1,041.60 | 1,116.00 | 1,190.40 |
| Variable costs | 505.98 | 548.15 | 590.32 | 632.48 | 674.65 |
| **Contribution** | **386.82** | **419.05** | **451.28** | **483.52** | **515.75** |
| Fixed costs (incl. depreciation and interest) | 262.47 | 257.05 | 251.17 | 245.62 | 240.13 |
| Break-even as % of installed capacity | 40.7 | 39.9 | 39.0 | 38.1 | 37.2 |
| Cash break-even as % of installed capacity | 32.4 | 32.6 | 32.6 | 32.5 | 32.3 |
| Break-even sales | 605.79 | 593.29 | 579.73 | 566.91 | 554.24 |




Break-even chart at Year 3 prices and costs, scaled to full capacity. Shaded areas show the loss zone (left) and profit zone (right).

Illustrative sample

# 19 Financial ratios

Liquidity and leverage improve over the projection. The current ratio stays at or above 1.88, while debt-equity drops from 1.63 to zero as the term loan is repaid.

| Ratio | Year 1 FY 2027-28 | Year 2 FY 2028-29 | Year 3 FY 2029-30 | Year 4 FY 2030-31 | Year 5 FY 2031-32 |
|---|---|---|---|---|---|
| Current ratio | 1.88 | 2.37 | 2.92 | 3.52 | 4.19 |
| Quick ratio | 1.38 | 1.84 | 2.36 | 2.94 | 3.57 |
| Debt-equity ratio (term loan / net worth) | 1.63 | 0.81 | 0.39 | 0.15 | 0.00 |
| Total outside liabilities / net worth | 2.53 | 1.38 | 0.79 | 0.44 | 0.23 |
| Interest coverage ratio | 3.24 | 4.28 | 5.84 | 8.32 | 13.17 |
| DSCR | 2.57 | 1.92 | 2.06 | 2.19 | 2.33 |
| Gross profit margin (%) | 38.6 | 38.9 | 39.2 | 39.5 | 39.6 |
| Operating profit (EBITDA) margin (%) | 26.2 | 26.7 | 27.1 | 27.5 | 27.7 |
| Net profit margin (%) | 10.4 | 12.6 | 14.4 | 16.0 | 17.4 |
| Return on capital employed (%) | 25.5 | 28.0 | 29.2 | 29.4 | 29.0 |
| Break-even (% of installed capacity) | 40.7 | 39.9 | 39.0 | 38.1 | 37.2 |

# 20 Key assumptions

- Commercial production starts in April 2027, and all assets are in use from the first year.
- Capacity utilisation of 60% in Year 1, rising to 80% by Year 5, over 300 working days a year.
- Selling price of ₹1.24 per tablet, excluding GST, held constant through the projection.
- Raw materials at 37.6% of sales, packing materials at 9.4%, power and fuel at 2.7%, and selling and distribution at 6.9%.
- Wages and salaries rise by 5% a year; repairs and administrative overheads rise by 5% a year.
- Working capital based on 45 days of raw material, 5 days of work in progress, 30 days of finished goods and 60 days of receivables, less 30 days of creditors.
- Term loan at 10.5% interest with a 6-month moratorium and 54 monthly instalments; cash credit at 11% on 75% of the working capital requirement.
- Depreciation on the written-down value method at Income Tax Act rates; income tax at a flat 25% of profit for simplicity.
- Contingency of 5% on building and machinery; preliminary and pre-operative expenses written off over five years.
- All amounts in ₹ lakh unless stated otherwise, excluding GST.

Illustrative sample

# 21 Conclusion

The model shows that a moringa tablets unit sized at 4,00,000 tablets per day can be financed 75:25 by a bank and its promoter, service its loan with an average DSCR of 2.21, and return about 30% a year on a project cost of ₹499.97 lakh. These are sample figures. A real project needs a report built on its own site, quotations and market.

**Need this report for your own plant?**

NPCS prepares detailed project reports and bank-format DPRs for your capacity, location and loan scheme, with machinery quotations, supplier lists and a market survey for your area.

Call or WhatsApp
+91 90970 75054

Email
npcs.india@gmail.com

Website
www.niir.org

This document is a computer-generated illustrative sample. The capacity, prices, costs and projections are representative assumptions for a typical small-scale unit and are not based on any specific project, location or quotation. Statutory requirements change and vary by state. Niir Project Consultancy Services accepts no liability for decisions taken on the basis of this sample.

Illustrative sample

# A Annexure: monthly loan repayment schedule

Term loan of ₹374.98 lakh at 10.5% a year. Amounts in ₹ lakh.

| No. | Month | Opening balance | Interest | Principal | Instalment | Closing balance |
|---|---|---|---|---|---|---|
| 1 | Apr 2027 | 374.98 | 3.28 | – | 3.28 | 374.98 |
| 2 | May 2027 | 374.98 | 3.28 | – | 3.28 | 374.98 |
| 3 | Jun 2027 | 374.98 | 3.28 | – | 3.28 | 374.98 |
| 4 | Jul 2027 | 374.98 | 3.28 | – | 3.28 | 374.98 |
| 5 | Aug 2027 | 374.98 | 3.28 | – | 3.28 | 374.98 |
| 6 | Sep 2027 | 374.98 | 3.28 | – | 3.28 | 374.98 |
| 7 | Oct 2027 | 374.98 | 3.28 | 5.46 | 8.74 | 369.52 |
| 8 | Nov 2027 | 369.52 | 3.23 | 5.51 | 8.74 | 364.01 |
| 9 | Dec 2027 | 364.01 | 3.19 | 5.56 | 8.74 | 358.45 |
| 10 | Jan 2028 | 358.45 | 3.14 | 5.61 | 8.74 | 352.84 |
| 11 | Feb 2028 | 352.84 | 3.09 | 5.66 | 8.74 | 347.19 |
| 12 | Mar 2028 | 347.19 | 3.04 | 5.71 | 8.74 | 341.48 |
| 13 | Apr 2028 | 341.48 | 2.99 | 5.76 | 8.74 | 335.73 |
| 14 | May 2028 | 335.73 | 2.94 | 5.81 | 8.74 | 329.92 |
| 15 | Jun 2028 | 329.92 | 2.89 | 5.86 | 8.74 | 324.07 |
| 16 | Jul 2028 | 324.07 | 2.84 | 5.91 | 8.74 | 318.16 |
| 17 | Aug 2028 | 318.16 | 2.78 | 5.96 | 8.74 | 312.20 |
| 18 | Sep 2028 | 312.20 | 2.73 | 6.01 | 8.74 | 306.19 |
| 19 | Oct 2028 | 306.19 | 2.68 | 6.06 | 8.74 | 300.12 |
| 20 | Nov 2028 | 300.12 | 2.63 | 6.12 | 8.74 | 294.01 |
| 21 | Dec 2028 | 294.01 | 2.57 | 6.17 | 8.74 | 287.84 |
| 22 | Jan 2029 | 287.84 | 2.52 | 6.22 | 8.74 | 281.61 |
| 23 | Feb 2029 | 281.61 | 2.46 | 6.28 | 8.74 | 275.33 |
| 24 | Mar 2029 | 275.33 | 2.41 | 6.33 | 8.74 | 269.00 |
| 25 | Apr 2029 | 269.00 | 2.35 | 6.39 | 8.74 | 262.61 |
| 26 | May 2029 | 262.61 | 2.30 | 6.45 | 8.74 | 256.16 |
| 27 | Jun 2029 | 256.16 | 2.24 | 6.50 | 8.74 | 249.66 |
| 28 | Jul 2029 | 249.66 | 2.18 | 6.56 | 8.74 | 243.10 |
| 29 | Aug 2029 | 243.10 | 2.13 | 6.62 | 8.74 | 236.49 |
| 30 | Sep 2029 | 236.49 | 2.07 | 6.67 | 8.74 | 229.81 |
| 31 | Oct 2029 | 229.81 | 2.01 | 6.73 | 8.74 | 223.08 |
| 32 | Nov 2029 | 223.08 | 1.95 | 6.79 | 8.74 | 216.29 |
| 33 | Dec 2029 | 216.29 | 1.89 | 6.85 | 8.74 | 209.44 |
| 34 | Jan 2030 | 209.44 | 1.83 | 6.91 | 8.74 | 202.53 |
| 35 | Feb 2030 | 202.53 | 1.77 | 6.97 | 8.74 | 195.56 |
| 36 | Mar 2030 | 195.56 | 1.71 | 7.03 | 8.74 | 188.53 |
| 37 | Apr 2030 | 188.53 | 1.65 | 7.09 | 8.74 | 181.43 |
| 38 | May 2030 | 181.43 | 1.59 | 7.16 | 8.74 | 174.28 |
| 39 | Jun 2030 | 174.28 | 1.52 | 7.22 | 8.74 | 167.06 |

Illustrative sample

| No. | Month | Opening balance | Interest | Principal | Instalment | Closing balance |
|---|---|---|---|---|---|---|
| 40 | Jul 2030 | 167.06 | 1.46 | 7.28 | 8.74 | 159.78 |
| 41 | Aug 2030 | 159.78 | 1.40 | 7.35 | 8.74 | 152.43 |
| 42 | Sep 2030 | 152.43 | 1.33 | 7.41 | 8.74 | 145.02 |
| 43 | Oct 2030 | 145.02 | 1.27 | 7.47 | 8.74 | 137.55 |
| 44 | Nov 2030 | 137.55 | 1.20 | 7.54 | 8.74 | 130.01 |
| 45 | Dec 2030 | 130.01 | 1.14 | 7.61 | 8.74 | 122.40 |
| 46 | Jan 2031 | 122.40 | 1.07 | 7.67 | 8.74 | 114.73 |
| 47 | Feb 2031 | 114.73 | 1.00 | 7.74 | 8.74 | 106.99 |
| 48 | Mar 2031 | 106.99 | 0.94 | 7.81 | 8.74 | 99.19 |
| 49 | Apr 2031 | 99.19 | 0.87 | 7.88 | 8.74 | 91.31 |
| 50 | May 2031 | 91.31 | 0.80 | 7.94 | 8.74 | 83.37 |
| 51 | Jun 2031 | 83.37 | 0.73 | 8.01 | 8.74 | 75.35 |
| 52 | Jul 2031 | 75.35 | 0.66 | 8.08 | 8.74 | 67.27 |
| 53 | Aug 2031 | 67.27 | 0.59 | 8.15 | 8.74 | 59.11 |
| 54 | Sep 2031 | 59.11 | 0.52 | 8.23 | 8.74 | 50.89 |
| 55 | Oct 2031 | 50.89 | 0.45 | 8.30 | 8.74 | 42.59 |
| 56 | Nov 2031 | 42.59 | 0.37 | 8.37 | 8.74 | 34.22 |
| 57 | Dec 2031 | 34.22 | 0.30 | 8.44 | 8.74 | 25.78 |
| 58 | Jan 2032 | 25.78 | 0.23 | 8.52 | 8.74 | 17.26 |
| 59 | Feb 2032 | 17.26 | 0.15 | 8.59 | 8.74 | 8.67 |
| 60 | Mar 2032 | 8.67 | 0.08 | 8.67 | 8.74 | – |

Illustrative sample